论文部分内容阅读
目的:探讨利培酮口服液治疗儿童孤独症的临床疗效及安全性。方法:对32儿童孤独症患者使用利培酮口服液治疗,观察12周。采用临床疗效总评量表(CGI)和孤独症治疗评估量表(ATEC)评定临床疗效,使用不良反应量表(TESS)及实验室监测评估安全性。结果:CGI中严重程度评分(SI)于治疗4周起与治疗前有所下降(P<0.05),于治疗12周下降更显著(P<0.01);疗效总评(GI)在治疗2周与治疗12周比较有显著性差异(P<0.01)。ATEC总分在治疗4周与治疗前比较有下降(P<0.05),于治疗12周下降更显著(P<0.01)。ATEC各项目分中,除社交项评分在治疗前后均无明显下降外(P>0.05),其他项目评分在治疗12周后均有明显下降(P<0.01),特别是行为项评分在治疗2周后与治疗前比较有显著性差异(P<0.05)。不良反应轻微,多自行缓解,17例(48.57%)患者有体质量增加。结论:利培酮口服液治疗儿童孤独症患者疗效确切,不良反应少,安全性高。
Objective: To investigate the clinical efficacy and safety of risperidone oral solution in children with autism. Methods: 32 children with autism were treated with oral risperidone for 12 weeks. Clinical efficacy was assessed using the Clinical Outcome Scale (CGI) and Autism Treatment Evaluation Scale (ATEC), and safety was assessed using the TESS and laboratory monitoring. Results: The severity score (SI) in CGI decreased from 4 weeks after treatment to before treatment (P <0.05), and decreased significantly at 12 weeks after treatment (P <0.01). The total effective rate (GI) After 12 weeks of treatment, there was a significant difference (P <0.01). ATEC score decreased 4 weeks after treatment and before treatment (P <0.05), but decreased more significantly at 12 weeks after treatment (P <0.01). The score of other items in all ATEC sub-categories except social scores did not decrease significantly before and after treatment (P> 0.05), and other items decreased significantly after 12 weeks of treatment (P <0.01), especially after 2 weeks of treatment Compared with before treatment, there was a significant difference (P <0.05). Minor adverse reactions, more self-remission, 17 cases (48.57%) patients with increased body mass. Conclusion: Risperidone oral solution treatment of children with autism has the exact effect, less adverse reactions and high safety.